ArticleInternational journal of ophthalmology2026
Screening for differentially expressed genes in retinoblastoma gene chips through the GEO database and validation in clinical settings.
Article in International journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo screen for differentially expressed genes in retinoblastoma (RB) gene chips using GEO2R and validate them clinically.
methodsThe expression profile chip data (GSE110811) was downloaded from the public gene chip database Gene Expression Omnibus (GEO). The GEO2R chip analysis platform was used to identify differentially expressed genes between RB and adjacent normal tissues. According to the International Intraocular Retinoblastoma Classification (IIRC) system, 35 children diagnosed with RB from our hospital and other hospitals were enrolled as the RB group, and 35 healthy children who underwent physical examinations in our hospital were enrolled as the control group. The relative expression levels of Sprouty RTK signaling antagonist 2 (SPRY2) and estrogen-related receptor beta (ESRRB) in the serum of patients were detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR). The diagnostic value of SPRY2 and ESRRB in RB was evaluated by receiver operating characteristic (ROC) curves. Analysis of the relationship between SPRY2/ESRRB expression and clinicopathological features, as well as its correlation with the tumor marker CA199.
resultsIn the GSE110811 chip, the expression levels of two genes, 16780069 (SPRY2) and 16786783 (ESRRB), showed the most significant differences between RB and normal tissues. The relative expression levels of SPRY2 and ESRRB in the serum of children in RB group (22 males, age 1.64±1.08y) were significantly lower (
conclusionThe expression of SPRY2 and ESRRB is closely related to the occurrence and development of RB and negatively correlated with the tumor marker CA199. They have the potential to serve as diagnostic biomarkers for RB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.